Drug
177Lu-DOTA-EB-TATE
177Lu-DOTA-EB-TATE is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
unknown1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
unknown133%
not_yet_recruiting133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_1
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
NCT06991738
recruitingphase_1
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
NCT05475210
unknownphase_1
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
NCT03308682
Clinical Trials (3)
Showing 3 of 3 trials
NCT06991738Phase 1
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
NCT05475210Phase 1
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
NCT03308682Phase 1
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3